(Q58215154)

9

0 references

Ann-Lii Cheng

object named as

Ann-Lii Cheng

10

0 references

author name string

Zhong-Zhe Lin

2

0 references

Chiun Hsu

3

0 references

Kuan-Der Lee

4

0 references

Chi-Huang Hsiao

5

0 references

Yen-Shen Lu

6

0 references

Chien-Chung Huang

7

0 references

Yin-Chun Shen

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

8

0 references

publication date

2012

0 references

published in

Oncology

0 references

volume

82

0 references

issue

1

0 references

page(s)

59-66

0 references

cites work

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

Salvage therapy for hepatocellular carcinoma with thalidomide

21 January 2018

1 reference

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

21 January 2018

1 reference

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

21 January 2018

1 reference

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma

21 January 2018

1 reference

Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy

21 January 2018

1 reference

Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

21 January 2018

1 reference

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

The interleukin-8 pathway in cancer.

21 January 2018

1 reference

Interleukin-6 and chronic inflammation

21 January 2018

1 reference

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.

21 January 2018

1 reference

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

21 January 2018

1 reference

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation

21 January 2018

1 reference

Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis.

21 January 2018

1 reference